Results 151 to 160 of about 108,047 (311)

Comparison of administration of oral versus Infusions intravenous iron therapy in diabetic patients with chronic kidney disease receiving Erythropoietin. [PDF]

Pak J Med Sci
Din N, Durrani A, Nouman MK, Haider B.
europepmc   +1 more source

GSH‐Responsive Nanoparticles Enhance Hepatocellular Carcinoma Immunotherapy Through Synergistic Effects of Cuproptosis and PI3K Inhibitor Combination

Advanced Science, EarlyView.
ABSTRACT Cuproptosis, an emerging form of programmed cell death, is capable of inducing mitochondrial dysfunction. Moreover, the PI3K‐AKT‐mTOR signaling pathway contributes to tumor cell progression by reprogramming mitochondrial morphology and function.
Lei Wu, Jintong Na, Xiyu Liu, Dongsheng Tang, Zhungang Yang, Zheng Cao, Xinyue He, Haihua Xiao, Liping Zhong, Yuan Liao, Yongxiang Zhao   +10 more
wiley   +1 more source

Safety assessment of intravenous immunoglobulins in pediatric population: A systematic review of adverse events. [PDF]

Medicine (Baltimore)
Altowairqi M, Kamal NM, Aljaber A, Alelyani AM, Alzaedi MA, Aljuaid SSS, Algethami AS, Oshi MAM, Soliman ASA.   +8 more
europepmc   +1 more source

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang, Lihuan Shang, Xiaochun Chen, Xiangzhan Kong, Xiaojuan Wang, Linjia Jiang, Huiying Zhao, Yafeng Zhu, Cheng Huang, Shiyi Deng, Rui Zhang, Minghui Wang, Haoming Lin, Ping‐Pui Wong   +13 more
wiley   +1 more source

Effects of a bidirectional interoperability between electronic health records and smart infusion pumps in hospital settings: a systematic review. [PDF]

BMJ Health Care Inform
Kuitunen S, Alves BL, Peitsoma H, Saleem MZ, Schepel L, Holmström AR.   +5 more
europepmc   +1 more source

Melarsoprol-Free Drug Combinations for Second-Stage Gambian Sleeping Sickness: The Way to Go. [PDF]

, 2007
Balasegaram, Brun, F. Chappuis, Priotto, P  pin, P  pin, Van Nieuwenhove   +6 more
core   +2 more sources

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Long-term relief of CRPS-associated limb dystonia with ketamine infusion. [PDF]

BMJ Case Rep
AlZahrani A, Weber-Adrian D, Ong MC.
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Administration of Intravenous Ferric Carboxymaltose in a Patient With Iron-Deficiency Anemia and Allergy to 2 Oral Iron Preparations. [PDF]

J Pediatr Pharmacol Ther
Wallace J, Trabal A.
europepmc   +1 more source